Abstract | Background: Objectives: Methods: Results: Fifteen and 22 men completed Cohorts 1 and 2, respectively. In Cohort 1, tenofovir diphosphate was 4.3-fold higher (95% CI geometric mean ratio 2.46-7.67; P = 0.0001) in dried blood spots and 2.3-fold higher (95% CI 1.09-4.92; P = 0.03) in PBMCs following 12 weeks of sofosbuvir + ribavirin versus study entry. Tenofovir in the plasma was unchanged. In Cohort 2, tenofovir diphosphate was 17.8-fold higher (95% CI 12.77-24.86; P < 0.0001) in dried blood spots after 8 weeks of ledipasvir/sofosbuvir versus study entry. Tenofovir plasma concentrations were 2.1-fold higher (95% CI 1.44-2.91; P = 0.0005). Despite the increase in cellular tenofovir diphosphate concentrations, only a small decline in CLCR (6%-7%) was observed in both cohorts between study entry and end of treatment. Conclusions: These data indicate an unexpected drug interaction with tenofovir disoproxil fumarate and sofosbuvir at the cellular level. Additional studies are needed to determine the mechanism and clinical significance.
|
Authors | Christine E MacBrayne, Kristen M Marks, Daniel S Fierer, Susanna Naggie, Raymond T Chung, Michael D Hughes, Arthur Y Kim, Marion G Peters, Diana M Brainard, Sharon M Seifert, Jose R Castillo-Mancilla, Lane R Bushman, Peter L Anderson, Jennifer J Kiser |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 73
Issue 8
Pg. 2112-2119
(08 01 2018)
ISSN: 1460-2091 [Electronic] England |
PMID | 29746648
(Publication Type: Clinical Trial, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiviral Agents
- Benzimidazoles
- Fluorenes
- Organophosphates
- ledipasvir, sofosbuvir drug combination
- tenofovir diphosphate
- Ribavirin
- Tenofovir
- Uridine Monophosphate
- Adenine
- Sofosbuvir
|
Topics |
- Adenine
(analogs & derivatives, pharmacokinetics, therapeutic use)
- Adult
- Antiviral Agents
(therapeutic use)
- Benzimidazoles
- Coinfection
(drug therapy)
- Drug Interactions
- Fluorenes
- HIV Infections
(drug therapy)
- Hepatitis C
(drug therapy)
- Humans
- Male
- Middle Aged
- Organophosphates
(pharmacokinetics, therapeutic use)
- Ribavirin
(therapeutic use)
- Sofosbuvir
(therapeutic use)
- Tenofovir
(pharmacokinetics, therapeutic use)
- Uridine Monophosphate
(analogs & derivatives)
|